BNT165e / BioNTech - LARVOL DELTA

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1/2 | N=177 | Active, not recruiting | Sponsor: BioNTech SE | Trial primary completion date: Sep 2025 ➔ May 2025

Trial primary completion date • Infectious Disease • Malaria

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination with an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1/2 | N=177 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Malaria

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination with an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1/2 | N=177 | Recruiting | Sponsor: BioNTech SE | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1/2 | N=108 | Recruiting | Sponsor: BioNTech SE

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1/2 | N=108 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting | N=160 ➔ 108

Enrollment change • Enrollment open • Infectious Disease • Malaria

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov) - P1/2 | N=160 | Not yet recruiting | Sponsor: BioNTech SE

New P1/2 trial • Infectious Disease • Malaria